Time course of C-reactive protein, tumour necrosis factor-alpha and monocyte chemoattractant protein-1 following the surgical treatment of patients with aortic valve stenosis

Hellenic Journal of Cardiology

Volumn 48, Issue 1, 2007, Pages 5-14

  Kastellanos, Stylianos S ^a,b   Toumpoulis, Ioannis K ^a   Aggeli, Constadina ^a   Zezas, Stefanos ^a   Chlapoutakis, Emmanouil ^a   Kastellanos, Stamatis ^a   Stefanadis, Christodoulos I ^a  

^a HIPPOKRATION HOSPITAL   (Greece)

^b NONE   (Greece)

Author keywords

Aortic valve stenosis; Inflammation markers

Indexed keywords

C REACTIVE PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; AORTA VALVE REPLACEMENT; AORTA VALVE STENOSIS; ARTICLE; BODY MASS; BODY SURFACE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; SEX DIFFERENCE; TIME; VENOUS BLOOD; BLOOD; HEART VALVE REPLACEMENT; MIDDLE AGED; POSTOPERATIVE PERIOD;

AGED; AORTIC VALVE STENOSIS; C-REACTIVE PROTEIN; CHEMOKINE CCL2; FEMALE; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE PERIOD; SEX FACTORS; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34247574193     PISSN: 10117970     EISSN: 10117970     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Rajamannan NM, Subramaniam M, Rickard D, et al: Human aortic valve calcification is associated with an osteoblast phenotype. Circulation 2003; 107: 2181-2184.
2. Rajamannan NM, Subramaniam M, Springett M, et al: Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve. Circulation 2002; 105: 2260-2265.
3. O'Brien KD, Kuusisto J, Reichenbach DD, et al: Osteopontin is expressed in human aortic valvular lesions. Circulation 1995; 92: 2163-2168.
4. Mohler ER, Gannon F, Reynolds C, et al: Bone formation and inflammation in cardiac valves. Circulation 2001; 103: 1522-1528.
5. Rajamannan NM, Gersh B, O'Bonow R, et al: Calcific aortic stenosis: From bench to the bedside - emerging clinical and cellular concepts. Heart 2003; 89: 801-805.
6. Caira F, Stock S, Gleason T, et al: Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation. J Am Coll Cardiol 2006; 47: 1707-1712.
7. Kaden J, Dempfle C, Grobholz, et al: Inflammation regulation of extracellular matrix remodeling in calcific aortic valve stenosis. Cardiovasc Pathol 2005; 14: 80-87.
8. Otto CM, Kuusisto J, Reichenback DD, et al: Characterization of the early lesion of 'degenerative' valvular aortic stenosis: histological and immunohistochemical studies. Circulation 1994; 90: 844-853.
9. Edep M, Shirani J, Brown D, et al: Matrix metalloproteinase expression in non-rheumatic aortic stenosis. Cardiovasc Pathol 2000; 9: 281-286.
10. Olsson M, Dalsgaard C, Haegestrand, et al: Accumulation of T lymphocytes and expression of interleukin-2 receptors in non-rheumatic stenotic aortic valves. J Am Coll Cardiol 1994; 23: 1162-1170.
11. Wallby L, Janerof-Sjoberg B, Steffensen T, et al: T lymphocyte infiltration in non-rheumatic stenotic aortic valves. Heart 2002; 88: 348-351.
12. Freeman R, Otto C, et al: Spectrum of calcific aortic valve disease pathogenesis disease progression. Circulation 2005; 111: 3616-3626.
13. Galante A, Pietroiusti A, Vellini M, et al: C-reactive protein is increased in patients with degenerative aortic valvular stenosis. J Am Coll Cardiol 2001; 38: 1078-1082.
14. Agmon Y, Khandheria B, Tajik J, et al: Inflammation and aortic valve sclerosis; Insights from the Olmsted county (Minnesota) population. Atherosclerosis 2004; 174: 337-342.
15. Kapadia S, Yakoob K, Nader S, et al: Elevated circulating levels of tumor necrosis factor-alpha in patents with hemodynamically significant pressure and volume overload. J Am Coll Cardiol 2000; 36: 208-212.
16. Froberg M, Adams A, Seacotte N, et al: Cytomegalovirus infection accelerates inflammation in valvular tissue overexpressing monocyte chemoattractant protein 1. Circ Res 2004; 94: 1310-1317.
17. Luster AD: Chemokines - chemotactic cytokines that mediate inflammation. N Eng J Med 1998; 338: 436-445.
18. Nelken N, Coughlin S, Gordon D, et al: Monocyte chemoattractant-1 in human atheromatous plaques. J Clin Invest 1991; 88: 1121-1127.
19. Ono SJ, Nakamura T, Miyazaki, et al: Chemokines: Roles in leukocyte development, trafficking, and effector function. J Allergy Clin Immunol 2003; 111: 118-199.
20. Gerber I, Steward R, Hammet J, et al: Effect of aortic valve replacement on C-reactive proteins in nonrheumatic aortic stenosis. Am J Cardiol 2003; 92: 1129-1132.
21. Chenillot O, Henny J, Steinmetz J, et al: High sensitivity Creactive protein: Biological variations and reference limits. Clin Chem Lab Med 2000; 38: 1003-1011.
22. HyCult Biotechnology B.v.: Product information and manual, Edition 01-02.
23. Ridker P: Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107: 363-369.
24. Murray DR, Freeman GL: Proinflammatory cytokines: predictors of a failing heart? Circulation 2003; 107: 1460-1462.
25. Sanchez P, Santos J, Kaski J, et al: Relation of circulating C-reactive protein to progression of aortic stenosis. Am J Cardiol 2006; 97: 90-93.
26. Fox CS, Guo C-Y, Larson M, et al: Relations of inflammation and novel risk factors to valvular calcification. Am J Cardiol 2006; 97: 1502-1505.
27. Skowash D, Schrempf S, Preusse C, et al: Tissue resident C-reactive protein in degenerative aortic valves: correlation with serum C-reactive concentrations and modification by statins. Heart 2006; 92: 495-498.
28. Kaden J, Dempfle C, Tran H, et al: Influence of C-reactive protein on matrix remodeling in calcific aortic stenosis. J Am Coll Cardiol 2004; 43 Suppl A: 433A (abstr).
29. Hein S, Arnon E, Kostin S, et al: Progression from compensated hypertrophy to failure in the pressure-overloaded human heart. Structural deterioration and compensatory mechanisms. Circulation 2003; 107: 984-991.
30. Libby P, Ridker P: Novel inflammatory markers of coronary risk: theory versus practice. Circulation 1999; 100: 1148-1150.
31. Blum A, Miller H: Role of cytokines in heart failure. Am Heart J 1998; 135: 181-186.
32. Francis G: TNFa and heart failure. Circulation 1999; 99: 3213-3214.
33. Bristow M: Tumor necrosis factor-a and cardiomyopathy. Circulation 1998; 97: 1340-1341.
34. Kaden J, Kilic R, Sarikoc A, et al: Tumor necrosis factor alpha promotes an osteoblast-like phenotype in human aortic valve myofibroblast: A potential regulatory mechanism of valvular calcification. Int J Mol Med 2005; 16: 869-872.
35. Vanderheyden M, Paulus W, Knuetermann V, et al: Myocardial cytokine gene expression is higher in aortic stenosis than in idiopathic dilated cardiomyopathy. Heart 2005; 91: 926-931.
36. Sheikine Y, Hansson G: Chemokines and atherosclerosis. Ann Med 2004; 36: 98-118.
37. Otto C, O'Brien K: Why is there a discordance between calcific aortic stenosis and coronary artery disease? Heart 2001; 85: 635-645.
38. Novaro G, Griffin B: Calcific aortic stenosis: another face of atherosclerosis. Cleve Clin J Med 2003; 70: 471-477.
39. Branch K, O'Brien K, Otto C: Aortic valve sclerosis as a marker of active atherosclerosis. Curr Cardiol Rep 2002; 4: 111-117.
40. Mohler E: Are atherosclerotic processes involved in aortic valve calcification? Lancet 2000; 356: 524-525.